Results 131 to 140 of about 10,049 (144)

A review of pregnancy and lactation postmarketing studies required by the FDA

Pharmacoepidemiology and Drug Safety, 2023
Leyla Şahin
exaly  

Postmarketing surveillance for drug abuse

Drug and Alcohol Dependence, 2003
Theodore Cicero, Cynthia Arfken
exaly  

Rivaroxaban postmarketing risk of liver injury

Journal of Hepatology, 2014
Gerd A Kullak-Ublick, Bruno Stieger, Stefan Russmann   +2 more
exaly  

Famotidine: Postmarketing Clinical Experience

Scandinavian Journal of Gastroenterology, 1987
K Saigenji
exaly  

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients

Modern Rheumatology, 2014
Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi   +2 more
exaly  

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients

Modern Rheumatology, 2012
Hisashi Yamanaka, Yoshiya Tanaka, Masayoshi Harigai   +2 more
exaly  

Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources

Seminars in Arthritis and Rheumatism, 2015
Samy Suissa
exaly  

Informatic Tools and Approaches in Postmarketing Pharmacovigilance Used by FDA

AAPS Journal, 2008
Mark I Avigan
exaly  

Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis

Modern Rheumatology, 2018
Atsushi Kawakami, Shigeki Momohara
exaly  

Sample Size and Postmarketing Surveillance

Drug Information Journal, 1985
Fred Schneiweiss
exaly